Clinicians' expectations for gene-driven cancer therapy
- PMID: 25574148
- PMCID: PMC4271717
- DOI: 10.4137/CMO.S20737
Clinicians' expectations for gene-driven cancer therapy
Abstract
A new era of medicine is rapidly approaching, which will change not only pathological diagnosis but also medical decision-making. This paper raises the question of how well prepared doctors are to address the new issues that will soon confront them. The human genome has been completely sequenced and general understanding about cancer biology has increased enormously with understanding that unregulated gene function and complicated changes in signal pathways are related to uncontrolled cell growth. Thus, gene-driven therapy involving alterations to genes are recognized to present new therapy options. This advance will necessitate major changes to the decision-making aspect of physicians. This article focuses on defining the pertinent changes and addressing what they mean for practicing physicians.
Keywords: gene alteration; individualized medicine; medical decision.
References
-
- Kuschel B, Lux MP, Goecke TO, Beckmann MW. Prevention and therapy for BRCA1/2 mutation carriers and women at high risk for breast and ovarian cancer. Eur J Cancer Prev. 2000;9(3):139–50. - PubMed
-
- Klemp JR, O’Dea A, Chamberlain C, Fabian CJ. Patient satisfaction of BRCA1/2 genetic testing by women at high risk for breast cancer participating in a prevention trial. Fam Cancer. 2005;4(4):279–84. - PubMed
-
- Surbone A. Social and ethical implications of BRCA testing. Ann Oncol. 2011;22(suppl 1):60–6. - PubMed
-
- Surbone A. Cultural competence: why? Ann Oncol. 2004;15(5):697–9. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources
